Devax's Axxess bifurcated drug-eluting stent is now available for sale in Europe, after the firm CE marked it. The self-expanding Nitinol stent, which elutes biolimus A9, is intended for bifurcated lesions. These occur in around 20% of patients treated with coronary angioplasty and ...
Please Login to read the full article.
